81. Cooper, AJM., et al. Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes. Diabetologia 2014; 57: 73–82.
82. Peddie MC, et al. Breaking prolonged sitting reduces postprandial glycemia in healthy, normal-weight adults: a randomized crossover trial. Am J Clin Nutr. 2013 Aug; 98(2): 358–366.
83. Duvivier, BMFM., et al. Breaking sitting with light activities vs structured exercise: A randomised crossover study demonstrating benefits for glycaemic control and insulin sensitivity in type 2 diabetes. Diabetologia 2017; 60: 490–498.
84. Buckley JP, et al. Standing-based office work shows encouraging signs of attenuating post-prandial glycaemic excursion. Occup Environ Med. 2014 Feb; 71(2): 109–111.
85. Falck RS, et al. What is the association between sedentary behaviour and cognitive function? A systematic review. Br J Sports Med. 2017; 51(10): 800–811.
86. Gill S., Panda S. Diurnal Eating Patterns in Humans that Can Be Modulated for Health Benefits. Cell metabolism 2015; 22(5): 789–798.
87. Spaeth, AM., et al. Phenotypic vulnerability of energy balance responses to sleep loss in healthy adults. Sci. Rep. 2015; 5: 14 920.
88. Bromley, LE, et al. Sleep restriction decreases the physical activity of adults at risk for type 2 diabetes. Sleep 2012; 35: 977–984.
89. Kootte, R.S.; Levin, E.; Salojarvi, J.; Smits, L.P.; Hartstra, A.V.; Udayappan, S.D.; Hermes, G.; Bouter, K.E.; Koopen, A.M.; Holst, J.J.; et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017; 26: 611–619e616.
90. Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020; 72: 558–577.
91. Ji Y, Yin Y, Li Z, Zhang W. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). Nutrients. (2019) 11: 1712.
92. Fianchi F, et al. Nonalcoholic fatty liver disease (Nafld) as model of gut-liver axis interaction: from pathophysiology to potential target of treatment for personalized therapy. Int J Mol Sci. 2021; 22: 6485.
93. Weintraub M, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992; 51(5): 586–594.
94. Connolly HM, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581–588.